経口抗糖尿病（OAD）治療の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Oral Antidiabetic (OAD) Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D005-00771 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール • 産業分類：医療・製薬

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、経口抗糖尿病（OAD）治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。経口抗糖尿病（OAD）治療の種類別市場規模（スルホニル尿素、ビグアニド、腸αグルコシダーゼ阻害剤、その他）、用途別市場規模（病院、クリニック、糖尿病治療センター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、Boehringer Ingelheim、Sanofi、Eli Lilly、Novartis、Merck、Mannkind、Glenmark、AstraZeneca、Novo Nordisk ・地域別グローバル市場分析 2015年-2020年 ・経口抗糖尿病（OAD）治療の北米市場（アメリカ、カナダ、メキシコ） ・経口抗糖尿病（OAD）治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・経口抗糖尿病（OAD）治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・経口抗糖尿病（OAD）治療の南米市場（ブラジル、アルゼンチン） ・経口抗糖尿病（OAD）治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：スルホニル尿素、ビグアニド、腸αグルコシダーゼ阻害剤、その他 ・用途別分析：病院、クリニック、糖尿病治療センター、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論

Market Overview
The global Oral Antidiabetic (OAD) Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Oral Antidiabetic (OAD) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Oral Antidiabetic (OAD) Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Oral Antidiabetic (OAD) Treatment market has been segmented into:
Sulphonylureas
Biguanides
Intestinal α-Glucosidase Inhibitors
Others

By Application, Oral Antidiabetic (OAD) Treatment has been segmented into:
Hospital
Clinics
Diabetics Treatment Centres
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Oral Antidiabetic (OAD) Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Oral Antidiabetic (OAD) Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Oral Antidiabetic (OAD) Treatment market.

The report offers in-depth assessment of the growth and other aspects of the Oral Antidiabetic (OAD) Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Oral Antidiabetic (OAD) Treatment Market Share Analysis
Oral Antidiabetic (OAD) Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Oral Antidiabetic (OAD) Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Oral Antidiabetic (OAD) Treatment sales, revenue and market share for each player covered in this report.

The major players covered in Oral Antidiabetic (OAD) Treatment are:
Pfizer
Boehringer Ingelheim
Sanofi
Eli Lilly
Novartis
Merck
Mannkind
Glenmark
AstraZeneca
Novo Nordisk

レポート目次

---

Table of Contents

1 Oral Antidiabetic (OAD) Treatment Market Overview
1.1 Product Overview and Scope of Oral Antidiabetic (OAD) Treatment
1.2 Classification of Oral Antidiabetic (OAD) Treatment by Type
1.2.1 Global Oral Antidiabetic (OAD) Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Type in 2019
1.2.3 Sulphonylureas
1.2.4 Biguanides
1.2.5 Intestinal α-Glucosidase Inhibitors
1.2.6 Others
1.3 Global Oral Antidiabetic (OAD) Treatment Market by Application
1.3.1 Overview: Global Oral Antidiabetic (OAD) Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Diabetics Treatment Centres
1.3.5 Others
1.4 Global Oral Antidiabetic (OAD) Treatment Market by Regions
1.4.1 Global Oral Antidiabetic (OAD) Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Oral Antidiabetic (OAD) Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Oral Antidiabetic (OAD) Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Oral Antidiabetic (OAD) Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Oral Antidiabetic (OAD) Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Oral Antidiabetic (OAD) Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Oral Antidiabetic (OAD) Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Boehringer Ingelheim
2.2.1 Boehringer Ingelheim Details
2.2.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Boehringer Ingelheim SWOT Analysis
2.2.4 Boehringer Ingelheim Product and Services
2.2.5 Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Sanofi SWOT Analysis
2.3.4 Sanofi Product and Services
2.3.5 Sanofi Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Eli Lilly SWOT Analysis
2.4.4 Eli Lilly Product and Services
2.4.5 Eli Lilly Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Novartis SWOT Analysis
2.5.4 Novartis Product and Services
2.5.5 Novartis Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Merck SWOT Analysis
2.6.4 Merck Product and Services
2.6.5 Merck Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Mannkind
2.7.1 Mannkind Details
2.7.2 Mannkind Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Mannkind SWOT Analysis
2.7.4 Mannkind Product and Services
2.7.5 Mannkind Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 Glenmark
2.8.1 Glenmark Details
2.8.2 Glenmark Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Glenmark SWOT Analysis
2.8.4 Glenmark Product and Services
2.8.5 Glenmark Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 AstraZeneca
2.9.1 AstraZeneca Details
2.9.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 AstraZeneca SWOT Analysis
2.9.4 AstraZeneca Product and Services
2.9.5 AstraZeneca Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.10 Novo Nordisk
2.10.1 Novo Nordisk Details
2.10.2 Novo Nordisk Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Novo Nordisk SWOT Analysis
2.10.4 Novo Nordisk Product and Services
2.10.5 Novo Nordisk Oral Antidiabetic (OAD) Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Oral Antidiabetic (OAD) Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Oral Antidiabetic (OAD) Treatment Players Market Share
3.2.2 Top 10 Oral Antidiabetic (OAD) Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Oral Antidiabetic (OAD) Treatment Revenue and Market Share by Regions
4.2 North America Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
5 North America Oral Antidiabetic (OAD) Treatment Revenue by Countries
5.1 North America Oral Antidiabetic (OAD) Treatment Revenue by Countries (2015-2020)
5.2 USA Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
6 Europe Oral Antidiabetic (OAD) Treatment Revenue by Countries
6.1 Europe Oral Antidiabetic (OAD) Treatment Revenue by Countries (2015-2020)
6.2 Germany Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
6.4 France Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue by Countries
7.1 Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue by Countries (2015-2020)
7.2 China Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
7.5 India Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
8 South America Oral Antidiabetic (OAD) Treatment Revenue by Countries
8.1 South America Oral Antidiabetic (OAD) Treatment Revenue by Countries (2015-2020)
8.2 Brazil Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Oral Antidiabetic (OAD) Treatment by Countries
9.1 Middle East & Africa Oral Antidiabetic (OAD) Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Oral Antidiabetic (OAD) Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Oral Antidiabetic (OAD) Treatment Market Forecast by Type (2019-2024)
10.3 Sulphonylureas Revenue Growth Rate (2015-2025)
10.4 Biguanides Revenue Growth Rate (2015-2025)
10.5 Intestinal α-Glucosidase Inhibitors Revenue Growth Rate (2015-2025)
10.6 Others Revenue Growth Rate (2015-2025)
11 Global Oral Antidiabetic (OAD) Treatment Market Segment by Application
11.1 Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Application (2015-2020)
11.2 Oral Antidiabetic (OAD) Treatment Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Diabetics Treatment Centres Revenue Growth (2015-2020)
11.6 Others Revenue Growth (2015-2020)
12 Global Oral Antidiabetic (OAD) Treatment Market Size Forecast (2021-2025)
12.1 Global Oral Antidiabetic (OAD) Treatment Market Size Forecast (2021-2025)
12.2 Global Oral Antidiabetic (OAD) Treatment Market Forecast by Regions (2021-2025)
12.3 North America Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2021-2025)
12.6 South America Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Oral Antidiabetic (OAD) Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Oral Antidiabetic (OAD) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Oral Antidiabetic (OAD) Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Oral Antidiabetic (OAD) Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Pfizer Corporate Information, Location and Competitors
Table 6. Pfizer Oral Antidiabetic (OAD) Treatment Major Business
Table 7. Pfizer Oral Antidiabetic (OAD) Treatment Total Revenue (USD Million) (2017-2018)
Table 8. Pfizer SWOT Analysis
Table 9. Pfizer Oral Antidiabetic (OAD) Treatment Product and Solutions
Table 10. Pfizer Oral Antidiabetic (OAD) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Boehringer Ingelheim Corporate Information, Location and Competitors
Table 12. Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Major Business
Table 13. Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Total Revenue (USD Million) (2018-2019)
Table 14. Boehringer Ingelheim SWOT Analysis
Table 15. Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Product and Solutions
Table 16. Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Sanofi Corporate Information, Location and Competitors
Table 18. Sanofi Oral Antidiabetic (OAD) Treatment Major Business
Table 19. Sanofi Oral Antidiabetic (OAD) Treatment Total Revenue (USD Million) (2017-2018)
Table 20. Sanofi SWOT Analysis
Table 21. Sanofi Oral Antidiabetic (OAD) Treatment Product and Solutions
Table 22. Sanofi Oral Antidiabetic (OAD) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Eli Lilly Corporate Information, Location and Competitors
Table 24. Eli Lilly Oral Antidiabetic (OAD) Treatment Major Business
Table 25. Eli Lilly Oral Antidiabetic (OAD) Treatment Total Revenue (USD Million) (2017-2018)
Table 26. Eli Lilly SWOT Analysis
Table 27. Eli Lilly Oral Antidiabetic (OAD) Treatment Product and Solutions
Table 28. Eli Lilly Oral Antidiabetic (OAD) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Novartis Corporate Information, Location and Competitors
Table 30. Novartis Oral Antidiabetic (OAD) Treatment Major Business
Table 31. Novartis Oral Antidiabetic (OAD) Treatment Total Revenue (USD Million) (2017-2018)
Table 32. Novartis SWOT Analysis
Table 33. Novartis Oral Antidiabetic (OAD) Treatment Product and Solutions
Table 34. Novartis Oral Antidiabetic (OAD) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Merck Corporate Information, Location and Competitors
Table 36. Merck Oral Antidiabetic (OAD) Treatment Major Business
Table 37. Merck Oral Antidiabetic (OAD) Treatment Total Revenue (USD Million) (2017-2018)
Table 38. Merck SWOT Analysis
Table 39. Merck Oral Antidiabetic (OAD) Treatment Product and Solutions
Table 40. Merck Oral Antidiabetic (OAD) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Mannkind Corporate Information, Location and Competitors
Table 42. Mannkind Oral Antidiabetic (OAD) Treatment Major Business
Table 43. Mannkind Oral Antidiabetic (OAD) Treatment Total Revenue (USD Million) (2017-2018)
Table 44. Mannkind SWOT Analysis
Table 45. Mannkind Oral Antidiabetic (OAD) Treatment Product and Solutions
Table 46. Mannkind Oral Antidiabetic (OAD) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Glenmark Corporate Information, Location and Competitors
Table 48. Glenmark Oral Antidiabetic (OAD) Treatment Major Business
Table 49. Glenmark Oral Antidiabetic (OAD) Treatment Total Revenue (USD Million) (2017-2018)
Table 50. Glenmark SWOT Analysis
Table 51. Glenmark Oral Antidiabetic (OAD) Treatment Product and Solutions
Table 52. Glenmark Oral Antidiabetic (OAD) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. AstraZeneca Corporate Information, Location and Competitors
Table 54. AstraZeneca Oral Antidiabetic (OAD) Treatment Major Business
Table 55. AstraZeneca Oral Antidiabetic (OAD) Treatment Total Revenue (USD Million) (2017-2018)
Table 56. AstraZeneca SWOT Analysis
Table 57. AstraZeneca Oral Antidiabetic (OAD) Treatment Product and Solutions
Table 58. AstraZeneca Oral Antidiabetic (OAD) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Novo Nordisk Corporate Information, Location and Competitors
Table 60. Novo Nordisk Oral Antidiabetic (OAD) Treatment Major Business
Table 61. Novo Nordisk Oral Antidiabetic (OAD) Treatment Total Revenue (USD Million) (2017-2018)
Table 62. Novo Nordisk SWOT Analysis
Table 63. Novo Nordisk Oral Antidiabetic (OAD) Treatment Product and Solutions
Table 64. Novo Nordisk Oral Antidiabetic (OAD) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Global Oral Antidiabetic (OAD) Treatment Revenue (Million USD) by Players (2015-2020)
Table 66. Global Oral Antidiabetic (OAD) Treatment Revenue Share by Players (2015-2020)
Table 67. Global Oral Antidiabetic (OAD) Treatment Revenue (Million USD) by Regions (2015-2020)
Table 68. Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Regions (2015-2020)
Table 69. North America Oral Antidiabetic (OAD) Treatment Revenue by Countries (2015-2020)
Table 70. North America Oral Antidiabetic (OAD) Treatment Revenue Market Share by Countries (2015-2020)
Table 71. Europe Oral Antidiabetic (OAD) Treatment Revenue (Million USD) by Countries (2015-2020)
Table 72. Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue (Million USD) by Countries (2015-2020)
Table 73. South America Oral Antidiabetic (OAD) Treatment Revenue by Countries (2015-2020)
Table 74. South America Oral Antidiabetic (OAD) Treatment Revenue Market Share by Countries (2015-2020)
Table 75. Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue (Million USD) by Countries (2015-2020)
Table 76. Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue Market Share by Countries (2015-2020)
Table 77. Global Oral Antidiabetic (OAD) Treatment Revenue (Million USD) by Type (2015-2020)
Table 78. Global Oral Antidiabetic (OAD) Treatment Revenue Share by Type (2015-2020)
Table 79. Global Oral Antidiabetic (OAD) Treatment Revenue Forecast by Type (2021-2025)
Table 80. Global Oral Antidiabetic (OAD) Treatment Revenue by Application (2015-2020)
Table 81. Global Oral Antidiabetic (OAD) Treatment Revenue Share by Application (2015-2020)
Table 82. Global Oral Antidiabetic (OAD) Treatment Revenue Forecast by Application (2021-2025)
Table 83. Global Oral Antidiabetic (OAD) Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Oral Antidiabetic (OAD) Treatment Picture
Figure 2. Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Type in 2019
Figure 3. Sulphonylureas Picture
Figure 4. Biguanides Picture
Figure 5. Intestinal α-Glucosidase Inhibitors Picture
Figure 6. Others Picture
Figure 7. Oral Antidiabetic (OAD) Treatment Revenue Market Share by Application in 2019
Figure 8. Hospital Picture
Figure 9. Clinics Picture
Figure 10. Diabetics Treatment Centres Picture
Figure 11. Others Picture
Figure 12. Global Oral Antidiabetic (OAD) Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Oral Antidiabetic (OAD) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Oral Antidiabetic (OAD) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Oral Antidiabetic (OAD) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Oral Antidiabetic (OAD) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Oral Antidiabetic (OAD) Treatment Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Oral Antidiabetic (OAD) Treatment Revenue Market Share in 2019
Figure 21. Global Top 10 Players Oral Antidiabetic (OAD) Treatment Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Oral Antidiabetic (OAD) Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Regions (2015-2020)
Figure 25. Global Oral Antidiabetic (OAD) Treatment Revenue Market Share by Regions in 2018
Figure 26. North America Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 27. Europe Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 29. South America Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 31. North America Oral Antidiabetic (OAD) Treatment Revenue Market Share by Countries (2015-2020)
Figure 32. North America Oral Antidiabetic (OAD) Treatment Revenue Market Share by Countries in 2019
Figure 33. USA Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 34. Canada Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 36. Europe Oral Antidiabetic (OAD) Treatment Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Oral Antidiabetic (OAD) Treatment Revenue Market Share by Countries in 2019
Figure 38. Germany Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 39. UK Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 40. France Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 41. Russia Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 42. Italy Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue Market Share by Countries in 2019
Figure 45. China Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 46. Japan Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 47. Korea Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 48. India Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 50. South America Oral Antidiabetic (OAD) Treatment Revenue Market Share by Countries (2015-2020)
Figure 51. South America Oral Antidiabetic (OAD) Treatment Revenue Market Share by Countries in 2019
Figure 52. Brazil Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 57. UAE Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Oral Antidiabetic (OAD) Treatment Revenue and Growth Rate (2015-2020)
Figure 60. Global Oral Antidiabetic (OAD) Treatment Revenue Share by Type (2015-2020)
Figure 61. Global Oral Antidiabetic (OAD) Treatment Revenue Share by Type in 2019
Figure 62. Global Oral Antidiabetic (OAD) Treatment Market Share Forecast by Type (2021-2025)
Figure 63. Global Sulphonylureas Revenue Growth Rate (2015-2020)
Figure 64. Global Biguanides Revenue Growth Rate (2015-2020)
Figure 65. Global Intestinal α-Glucosidase Inhibitors Revenue Growth Rate (2015-2020)
Figure 66. Global Others Revenue Growth Rate (2015-2020)
Figure 67. Global Oral Antidiabetic (OAD) Treatment Revenue Share by Application (2015-2020)
Figure 68. Global Oral Antidiabetic (OAD) Treatment Revenue Share by Application in 2019
Figure 69. Global Oral Antidiabetic (OAD) Treatment Market Share Forecast by Application (2021-2025)
Figure 70. Global Hospital Revenue Growth Rate (2015-2020)
Figure 71. Global Clinics Revenue Growth Rate (2015-2020)
Figure 72. Global Diabetics Treatment Centres Revenue Growth Rate (2015-2020)
Figure 73. Global Others Revenue Growth Rate (2015-2020)
Figure 74. Global Oral Antidiabetic (OAD) Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Oral Antidiabetic (OAD) Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Oral Antidiabetic (OAD) Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2021-2025)
Figure 78. Europe Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2021-2025)
Figure 80. South America Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel

---